News|Articles|July 18, 2017

PTSM: Pharmaceutical Technology Sourcing and Management

  • PTSM: Pharmaceutical Technology Sourcing and Management-08-02-2017
  • Volume 12
  • Issue 8

Alcami Relocates Headquarters to Research Triangle Park, NC

Alcami will move its headquarters to Durham, NC while maintaining its manufacturing and laboratory operations in Wilmington, NC.

Alcami, a custom development and manufacturing service provider for the pharmaceutical and biotechnology industries, announced on July 14, 2017 plans to transition its global headquarters from Wilmington, NC to Research Triangle Park in Durham, NC.

The company currently employs approximately 50 people at its Durham laboratory services site and anticipates adding new jobs to support its technology expansion into biologics and the establishment of its new headquarters location in 2018. The company reports it will continue to house executive offices in both its current Wilmington headquarters and the Durham facilities until the full transition is complete.

“We are very excited about this relocation, which prominently positions Alcami in a region known for its culture of diverse expertise, cutting-edge innovation, and invention,” stated Dr. Stephan Kutzer, Alcami president and chief executive officer, in a company press release. “Our stronger presence in the Triangle is necessary to meet the evolving needs of our clients, accommodate growth, recruit top talent, and attract investors and new customers.”

The company noted in the press statement that it remains committed to the Wilmington manufacturing and laboratory site, which employs more than 450 people. The company recently invested approximately $6 million as part of a 5000-sq.-ft. laboratory services expansion and serialization upgrade for drug product packaging. The Wilmington operations account for approximately 35% of the company’s overall business.

“North Carolina is home to Alcami, and our expansion in the Research Triangle Park area is an investment in the future of the company,” Kutzer said.

Source: Alcami

 

 


Related to this article

CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 1
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation. | Image Credit: ©HockleyMedia24/peopleimages.com -stock.adobe.com
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.